Navigation Links
Reportlinker Adds Global Bladder Cancer Therapeutics Industry
Date:11/18/2010

mp; Future Analysis for

Bladder Cancer Therapeutics by Geographic Region - US, Japan,

Europe, and Rest of World Markets Independently Analyzed by

Annual Revenues in US$ Million for the Years 2007 through 2015

(includes corresponding Graph/Chart) II-69

Table 11: World Historic Review for Bladder Cancer

Therapeutics by Geographic Region - US, Japan, Europe, and

Rest of World Markets Independently Analyzed by Annual

Revenues in US$ Million for the Years 2001 through 2006

(includes corresponding Graph/Chart) II-70

Table 12: World 11-Year Perspective for Bladder Cancer

Therapeutics by Geographic Region - Percentage Breakdown of

Revenues for US, Japan, Europe, and Rest of World Markets for

the Years 2005, 2010 & 2015 (includes corresponding

Graph/Chart) II-71

III. MARKET

1. UNITED STATES III-1

A.Market Analysis III-1

Bladder Cancer & Prevalence - A Recapitulation of Facts III-1

Mortality Rates Higher in African Americans III-2

Table 13: Incidence of Bladder Cancer Among African

Americans (Males): Percentage Share Breakdown by Select

Cancer/Type or Site and Gender for the Year 2007 (includes

corresponding Graph/Chart) III-2

Bladder Cancer - A Costly Urologic Condition III-3

Table 14: Urologic Disease Costs in the US: 2006 (includes

corresponding Graph/Chart) III-3

US Bladder Cancer Statistics III-3

Table 15: Bladder Cancer Prevalence and Mortality in the US

by Gender: Percentage Share Breakdown for 2009 III-3

Table 16: Bladder Cancer Incidence in the US by Gender:

Percentage Share Breakdown for 2008 III-3

FDA Approval III-4

Strategic Corporate Developments III-6

Select Players III-12

Allergan, Inc. III-12

Allos Therapeutics, Inc. III-13

AVI BioPharma, Inc. III-13

Bristol-Myers Squibb Company III-14

<
'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Reportlinker Adds Infectious Disease Molecular Diagnostic Testing
2. Reportlinker Adds Smart Glass: Technologies and Global Markets Report
3. Reportlinker Adds Synthetic Biology: Emerging Global Markets Report
4. Reportlinker Adds Proteomics: Technologies and Global Markets Report
5. Reportlinker Adds Nanomedicine Report
6. Reportlinker Adds Small Molecule Kinase Inhibitors Report
7. Reportlinker Adds Nanoporous Materials Report
8. Reportlinker Adds Membrane Bioreactors Report
9. Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement
10. Reportlinker Adds High-Tech Patient Monitoring Systems Markets (Remote and Wireless Systems, Data Processing, EMR Data Transfer) Report
11. Reportlinker Adds In Vitro Diagnostics in a Recession: IVD Market Forecasts, Analysis and Success Strategies Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... (PRWEB) August 21, 2014 ... biopharmaceutical contract development and manufacturing organization (CMO) announced ... Pharmaceuticals, Inc., an oncology company focused on the ... cancer, to manufacture the anti-prostate specific membrane antigen ... product candidate. Under the agreement the antibody ...
(Date:8/21/2014)... of last week RENU 28, the world's first and only ... purchase in Australia and New Zealand, and the response has ... if you think about the definition of aging, it's really ... your body. If you think about the definition of anti-aging, ... RENU 28 does is it works with these tiny little ...
(Date:8/20/2014)... inventions licensed to biotechnology firms has revealed early ... these roadblocks, the researchers suggest that better communication ... could lead to faster commercialization down the road. ... made in university laboratories and licensed to biotechnology ... which have a high failure rate. But a ...
(Date:8/20/2014)... measuring vibrational motion of a single molecule with a ... a single molecule differs from the behaviour of larger ... the University of California, Irvine, where post-doctoral researcher Eero ... visiting fellow under professor Vartkess A. Apkarian, whose team ... by Professor Eric O. Potma. The results of the ...
Breaking Biology Technology:Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 3RENU 28 Skin Care Now Available in Australia and New Zealand 2Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3Seeing a molecule breathe 2
... Bulletin Board: TBIO ) today announced that ... Director for Laboratory Services.  In this newly created position ... vision and managing the day-to-day operations of Transgenomic,s Molecular ... to Transgenomic nearly 20 years of genetics experience in ...
... 21 Sermo ( http://www.sermo.com ), the largest online ... titled, " Physician Participation in the ESA REMS Program ... in the FDA-required Erythropoiesis-Stimulating Agents (ESAs) risk evaluation and ... results, 83% of Hematologists/Oncologists view the ESA REMS program ...
... HIGHLIGHTS:   2010 Results (all percentages are ... reported sales increased 5% to $563 million. Excluding foreign currency exchange ... for SAFC (Fine Chemicals) and Research Products increased 12% and 3%, ... and 5%, respectively. Q3 2010 reported diluted EPS ...
Cached Biology Technology:Dr. Eric Johnson Joins Transgenomic as Medical Director for Laboratory Services 2Dr. Eric Johnson Joins Transgenomic as Medical Director for Laboratory Services 3Dr. Eric Johnson Joins Transgenomic as Medical Director for Laboratory Services 4Sermo Report Indicates Possible Decline in Prescribing of Erythropoiesis-Stimulating Agents 2Sigma-Aldrich (Nasdaq: SIAL) Reports Q3 2010 Diluted EPS of $0.76. Diluted EPS Increased by 9% and 19% on a Reported and Adjusted Basis, Respectively. Q3 Sales Performance Remains Strong; Full Year 2010 Diluted Adjusted EPS Outlook Raised to $3.20 - 2Sigma-Aldrich (Nasdaq: SIAL) Reports Q3 2010 Diluted EPS of $0.76. Diluted EPS Increased by 9% and 19% on a Reported and Adjusted Basis, Respectively. Q3 Sales Performance Remains Strong; Full Year 2010 Diluted Adjusted EPS Outlook Raised to $3.20 - 3Sigma-Aldrich (Nasdaq: SIAL) Reports Q3 2010 Diluted EPS of $0.76. Diluted EPS Increased by 9% and 19% on a Reported and Adjusted Basis, Respectively. Q3 Sales Performance Remains Strong; Full Year 2010 Diluted Adjusted EPS Outlook Raised to $3.20 - 4Sigma-Aldrich (Nasdaq: SIAL) Reports Q3 2010 Diluted EPS of $0.76. Diluted EPS Increased by 9% and 19% on a Reported and Adjusted Basis, Respectively. Q3 Sales Performance Remains Strong; Full Year 2010 Diluted Adjusted EPS Outlook Raised to $3.20 - 5Sigma-Aldrich (Nasdaq: SIAL) Reports Q3 2010 Diluted EPS of $0.76. Diluted EPS Increased by 9% and 19% on a Reported and Adjusted Basis, Respectively. Q3 Sales Performance Remains Strong; Full Year 2010 Diluted Adjusted EPS Outlook Raised to $3.20 - 6Sigma-Aldrich (Nasdaq: SIAL) Reports Q3 2010 Diluted EPS of $0.76. Diluted EPS Increased by 9% and 19% on a Reported and Adjusted Basis, Respectively. Q3 Sales Performance Remains Strong; Full Year 2010 Diluted Adjusted EPS Outlook Raised to $3.20 - 7Sigma-Aldrich (Nasdaq: SIAL) Reports Q3 2010 Diluted EPS of $0.76. Diluted EPS Increased by 9% and 19% on a Reported and Adjusted Basis, Respectively. Q3 Sales Performance Remains Strong; Full Year 2010 Diluted Adjusted EPS Outlook Raised to $3.20 - 8Sigma-Aldrich (Nasdaq: SIAL) Reports Q3 2010 Diluted EPS of $0.76. Diluted EPS Increased by 9% and 19% on a Reported and Adjusted Basis, Respectively. Q3 Sales Performance Remains Strong; Full Year 2010 Diluted Adjusted EPS Outlook Raised to $3.20 - 9Sigma-Aldrich (Nasdaq: SIAL) Reports Q3 2010 Diluted EPS of $0.76. Diluted EPS Increased by 9% and 19% on a Reported and Adjusted Basis, Respectively. Q3 Sales Performance Remains Strong; Full Year 2010 Diluted Adjusted EPS Outlook Raised to $3.20 - 10Sigma-Aldrich (Nasdaq: SIAL) Reports Q3 2010 Diluted EPS of $0.76. Diluted EPS Increased by 9% and 19% on a Reported and Adjusted Basis, Respectively. Q3 Sales Performance Remains Strong; Full Year 2010 Diluted Adjusted EPS Outlook Raised to $3.20 - 11Sigma-Aldrich (Nasdaq: SIAL) Reports Q3 2010 Diluted EPS of $0.76. Diluted EPS Increased by 9% and 19% on a Reported and Adjusted Basis, Respectively. Q3 Sales Performance Remains Strong; Full Year 2010 Diluted Adjusted EPS Outlook Raised to $3.20 - 12
(Date:8/21/2014)... 18-22, 2014 , WHERE: , San Diego ... CA 92101 , WHAT: , Invited and ... latest research in human genetics. Examples of sessions ... on rare genetic variants in health and disease, ... sun sensitivity (Saturday, Oct. 18, 5:30-7:30 pm) , ...
(Date:8/21/2014)... State University have developed a novel and versatile modeling ... for creating new materials as well as for studying ... allows us to model much larger and more complex ... says Nan Li, lead author of a paper on ... Department of Materials Science and Engineering. "This is a ...
(Date:8/20/2014)... finds life can persist in a cold, dark world. ... team that examined waters and sediments from a shallow ... the extreme environment supports microbial ecosystems. , The ... colleagues has implications for life in other extreme environments, ... findings are published in the current edition of the ...
Breaking Biology News(10 mins):American Society of Human Genetics 2014 Annual Meeting 2Researchers develop models to study polyelectrolytes, including DNA and RNA 2University of Tennessee research uncovers subglacial life beneath Antarctic ice sheet 2
... Engineering Conferences International (ECI) ( info@engconfintl.org ... XII Conference ( http://www.engconfintl.org/10ac.html ) are proud ... the winner of the 2010 Cell Culture ... Professor of Chemical and Biomolecular Engineering, at ...
... the Iberian Peninsula usually exceed the protection threshold established by ... according to data gathered between 2000 and 2005 by four ... Doana National Park. The limits established to protect human ... usually exceeded from April onwards, especially during the summer, in ...
... Langone Medical Center researchers have developed a powerful new method ... genes and examine how the process goes wrong in cancer ... research and described in the April 9 issue of ... DNA, a process required for gene activation. "The ...
Cached Biology News:Michael Betenbaugh wins 2010 Cell Culture Engineering award 2Ozone levels tend to be above recommended levels at this time of year in South West Spain 2Powerful new method allows scientists to probe gene activation 2
... is a four-channel general purpose laboratory amplifier. It ... sources which may have a large common-mode level ... a high gain/low noise amplifier, an input coupling ... offset control. A control knob sets the amplifier ...
... Pro-OpioMelanoCortin (POMC) has long been ... prime precursor to a multiplicity of ... (-LPH), -endorphin, Alpha-Melanocyte Stimulating Hormone (a-MSH) ... very well-conserved molecule, being found in ...
...
...
Biology Products: